Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial

Introduction Netakimab (NTK), an original humanized anti-interleukin-17 monoclonal antibody, showed therapeutic efficacy in moderate-to-severe plaque psoriasis in a phase 2 clinical study. Herein we report the results of 54 weeks of a phase 3 PLANETA trial aimed to evaluate the efficacy and safety o...

Full description

Saved in:

Bibliographic Details
Published in:	Dermatology and therapy Vol. 11; no. 4; pp. 1319 - 1332
Main Authors:	Puig, Luís, Bakulev, Andrey L., Kokhan, Muza M., Samtsov, Alexey V., Khairutdinov, Vladislav R., Morozova, Maria A., Zolkin, Nikita A., Kuryshev, Ivan V., Petrov, Alexey N., Artemeva, Antonina V., Zinkina-Orikhan, Arina V.
Format:	Journal Article
Language:	English
Published:	Cheshire Springer Healthcare 01.08.2021 Springer Springer Nature B.V
Subjects:	Analysis Arthritis Clinical trials Cytokines Dermatology Development and progression Dosage and administration Drug dosages Drug therapy Hypotheses Interleukins Internal Medicine Light therapy Medicine Medicine & Public Health Monoclonal antibodies NCT NCT03390101 Oral and Maxillofacial Surgery Original Research Patients Plastic Surgery Psoriasis Quality of Life Research Response rates Sample size Skin Statistical analysis Tuberculosis Russia Belarus Psoriasis Interleukin-17 inhibitors Netakimab
ISSN:	2193-8210, 2190-9172
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!